A multi-institutional phase I study of acetazolamide with temozolomide in adults with newly diagnosed MGMT -methylated malignant glioma.

Riley K Driscoll Seán B Lyne David J VoceStefania MarakaVinai GondiSteven J Chmura Karan S Dixit Priya U KumthekarTheodore G KarrisonPeter PytelJohn M CollinsRoger StuppRyan T MerrellRimas V Lukas Bakhtiar Yamini

Published in: Neuro-oncology advances (2024)

methylated GBM and support examination of acetazolamide in a randomized trial. BCL-3 expression is a potential biomarker for prognosis in GBM or for patients more likely to benefit from TMZ.

Keyphrases

newly diagnosed
end stage renal disease
poor prognosis
ejection fraction
chronic kidney disease
peritoneal dialysis
binding protein
long non coding rna